Welcome back to the channel. This is Plenary Session podcast, video and audio edition.

I'll give the same plug I've given before. If you're listening to the audio version, I want you to hit the pause button and go take a look at the video.

For my ASCO coverage, I'm doing a lot of visuals, and as they say, a picture's worth a thousand words now look I'm not happy about it either I'm like you I prefer to

listen to content audio only when I want to go I don't got time to look at any

videos but for this make an exception I urge you make an exception we have done

two videos previously on this channel we've done of course shine that great

trial that Ibrutinibirr versus BR trial that's shining a piece of, well, you know, you know what it is.

We've also done CT-guided DNA in the adjuvant setting, and I think that's dynamic, dynamic.

Here we're doing determination, the third one, determination.

We're going to do Destiny Breast 4, don't worry, we're coming to that.

And we might even do that Luis Diaz, locally advanced rectal cancer paper in New England Journal.

But we're going to do a lot of these. I'm going to try to do as many as I can. I got to do determination.

This is, we are determined to keep doing transplant. That's what they might as well have called it. We're determined to hit it. Okay, this is multiple myeloma. We're switching a lot of hats here.

First, we are in the mantel cell lymphoma space.

Then we're in the adjuvant stage two colon space.

And now we're in multiple myeloma.

My favorite stomping ground, you know me.

I love thinking about multiple myeloma. And I had a blistering podcast a few weeks ago where I talked about

how it's a field that probably is one of the most captured because you have so many randomized

control trials and you just don't even know basics. What's the best second line therapy? Does

anyone actually have a survival benefit from auto, you know, et cetera, et cetera. And there are many

other questions. And what is even the

...